Loading stock data…
$0.55-0.00 (-0.86%)
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union.
Onconetix, Inc. in the Healthcare sector is trading at $0.55 with a market capitalization of $4M. The stock is currently near its 52-week low of $0.54, remaining 97.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17,120↓ | $21,457↓ | $303,596 | $303,651↑ | $106,494 |
| Gross Profit | $4,303↑ | -$1,655↓ | $247,684↓ | $268,894↑ | $70,503 |
| Operating Income | -$2.24M↓ | -$2.09M↓ | -$1.28M↑ | -$2.07M↓ | -$1.34M |
| Net Income | -$2.87M↑ | -$4.21M↓ | $5.67M↑ | -$8.78M↓ | -$2.37M |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vit...